Entertainment
HUTCHMED Announces NDA Acceptance In China With Priority Review Status For ORPATHYS® And TAGRISSO® Combination In Lung Cancer Patients With MET Amplification After Progression On First-Line EGFR Inhibitor Therapy
(MENAFN - GlobeNewsWire - Nasdaq) HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (–HUTCHMED–) (Nasdaq/AIM:HCM; HKEX:13) today announces ...
By: menafn
- Jan 02 2025
- 0
- 0 Views
Share this page
Guest Posts by Easy Branches
